Bofanglutide linked to meaningful reductions in HbA1c in adults with T2DM

For adults with benignant 2 diabetes mellitus (T2DM), bofanglutide, a glucagon-like peptide-1 receptor agonist, is associated with much meaningful reductions successful hemoglobin A1C (HbA1c) levels than semaglutide, according to a survey published online June 30 successful the Annals of Internal Medicine.